21
Jul
Artificial intelligence to improve drug combination design and personalized medicine
Comments
A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine.
The auto-commentary builds on a study recently published by the authors in Science Translational Medicine about an artificial intelligence (AI) platform, Quadratic Phenotypic Optimization Platform (QPOP), that substantially improves combination therapy in bortezomib-resistant multiple myeloma to identify the best drug combinations for individual multiple myeloma patients.
Artificial intelligence to improve drug (AI)
It is now evident that complex diseases, such as cancer, often require effective drug combinations to make any significant therapeutic impact. As the drugs in these combination therapies become increasingly specific to molecular targets, designing effective drug combinations as well as choosing the right drug combination for the right patient becomes more difficult.
